References
- Arend W P, Dayer J M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis. Arthritis Rheum 1995; 38: 151–60
- Bendtzen K. Cytokines and natural regulators of cytokines. Immunol Lett 1994; 43: 111–23
- Dinarello C A, Thompson R C. Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro. Immunol Today 1991; 12: 404–10
- Hansen M B, Svenson M, Abell K, Vanning K, Nielsen H P, Bertelsen A, et al. Sex- and age dependency of IgG autoantibodies against IL-1 alpha in healthy humans. Eur J Clin Invest 1994; 24: 212–8
- Suzuki H, Kamimura J, Ayabe T, Kashiwagi H. Demonstration of neutralizing autoantibodies against IL-1 alpha in sera from patients with rheumatoid arthritis. J Immunol 1990; 145: 2140–6
- Svenson M, Hansen M B, Kayser L, Rasmussen Å K, Reimert C M, Bendtzen K. Effects of human anti-IL-1 alpha autoantibodies on receptor binding and biological activities of IL-1 alpha. Cytokine 1992; 4: 125–33
- Kvien T K, Hoyeraal H M, Kass E. Diagnostic criteria of rheumatoid arthritis in children. Proposed criteria for controlled clinical studies. Scand J Rheumatol 1982; 11: 187–92
- Kvien T K, Høyeraal H M, Sandstad B. Assessment methods of disease activity in juvenile rheumatoid arthritis — evaluated in a prednisolone/placebo double-blind study. J Rheumatol 1982; 9: 696–702
- Steinbrocker M, Traeger C H, Batterman R C. Therapeutic criteria in rheumatoid arthritis. JAMA 1949; 140: 659–62
- Svenson M, Poulsen L K, Fomsgaard A, Bendtzen K. IgG autoantibodies against interleukin 1 alpha in sera of normal individuals. Scand J Immunol 1989; 29: 489–92
- Wilson C B. Immunologic basis for increased susceptibility of the neonate to infection. J Pediatr 1986; 108: 1–12